Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Iceland

European Innovation Council · Finished

DNACA Dementia/Alzheimer Drug Attributed to Cystatin-C and other mutations – precision medicine drug development

Coordinator
Arctic Therapeutics Ehf, Iceland
Runs
1 March 2023 to 28 February 2025
Status
Finished
EU funding
€2.5m
Total cost
€3.6m
Partners
1 organisations in 1 countries
Type
European Innovation Council
Grant agreement
190174464

What the project is doing

In the project's own words, from its summary on CORDIS.

With an aging population and >55 million dementia cases worldwide; treatments are more needed than ever. However, effective treatments are lacking, with solutions only stalling dementia progress and no real disease-modifying effect. ATI has developed AT-001, a new drug with the potential to stop and revert the disease, and to delay its onset. AT-001 has been developed through the DNACA precision-medicine based platform, which applies Big Data mining and Deep Learning/AI algorithms to identify patients with validated biomarkers.

AT-001 is different in that it prevents aggregation of amyloid/tau proteins, common in many types of dementia. Phase IIa clinical trials have shown strong effects in the treatment of HCCAA. We will now carry out a registration trial for commercialization in Iceland and POC studies in Europe to obtain NDA in familial dementia, thereby informing the treatment of Alzheimer’s Disease (60% of dementia cases), potentially changing the lives of millions for the better.

Topics

Who is involved

OrganisationCityCountryRole
Arctic Therapeutics EhfReykjavikIcelandCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI